BTIG Research Forecasts Strong Price Appreciation for United Therapeutics (NASDAQ:UTHR) Stock

Key Points

• BTIG Research raised its price target on United Therapeutics from $728 to $768 and maintained a Buy rating, implying 27.37% upside from the prior close.
• Third-quarter revenue rose 4.1% year over year to $832.5 million, beating estimates, but earnings of $5.71 per share fell short of the $6.01 consensus and were down from $7.16 a year earlier.
• The company has authorized a $2 billion share repurchase program, allowing it to buy back up to 8.3% of its outstanding shares.

United Therapeutics (NASDAQ:UTHR - Get Free Report) had its price objective hoisted by stock analysts at BTIG Research from $728.00 to $768.00 in a report issued on Wednesday, Benzinga reports. The brokerage presently has a "buy" rating on the biotechnology company's stock. BTIG Research's price objective would indicate a potential upside of 27.37% from the company's previous close.

A number of other equities research analysts have also recently issued reports on UTHR. Raymond James Financial restated an "outperform" rating and set a $717.00 price objective on shares of United Therapeutics in a report on Tuesday, October 20th. Leerink Partners lifted their price target on United Therapeutics from $685.00 to $725.00 and gave the stock an "outperform" rating in a report on Monday, October 19th. Royal Bank Of Canada dropped their price target on United Therapeutics from $708.00 to $697.00 and set an "outperform" rating for the company in a report on Thursday, October 22nd. Bank of America reduced their price target on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a research note on Friday, July 10th. Finally, Weiss Ratings lowered United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a report on Thursday, August 27th. Thirteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $673.80.

United Therapeutics Stock Up 0.3%

Shares of UTHR traded up $1.66 during trading hours on Wednesday, hitting $602.98. The company had a trading volume of 419,894 shares, compared to its average volume of 554,787. The business has a fifty day moving average of $530.53 and a 200-day moving average of $531.77. The firm has a market cap of $25.86 billion, a price-to-earnings ratio of 21.49, a PEG ratio of 4.32 and a beta of 0.49. United Therapeutics has a 12 month low of $432.53 and a 12 month high of $609.99.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 EPS for the quarter, missing the consensus estimate of $6.01 by ($0.30). The company had revenue of $832.50 million for the quarter, compared to the consensus estimate of $781.14 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The business's quarterly revenue was up 4.1% on a year-over-year basis. During the same period in the previous year, the firm posted $7.16 EPS. On average, equities analysts expect that United Therapeutics will post 26.09 EPS for the current fiscal year.

United Therapeutics declared that its Board of Directors has initiated a share buyback program on Thursday, October 22nd that allows the company to buy back $2 billion in outstanding shares. This buyback authorization allows the biotechnology company to reacquire up to 8.3% of its stock through open market purchases. Stock buyback programs are typically an indication that the company's board believes its stock is undervalued.

Insider Activity at United Therapeutics

In other news, CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $526.96, for a total value of $5,006,120.00. Following the completion of the sale, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $170,968,483.28. The trade was a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 401,528 shares of company stock worth $211,631,836 over the last quarter. 8.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On United Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Arjuna Capital increased its position in shares of United Therapeutics by 2.8% during the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company's stock worth $393,000 after acquiring an additional 18 shares in the last quarter. Abacus Wealth Partners LLC lifted its position in United Therapeutics by 5.6% in the 3rd quarter. Abacus Wealth Partners LLC now owns 396 shares of the biotechnology company's stock valued at $215,000 after acquiring an additional 21 shares in the last quarter. Sage Rhino Capital LLC lifted its position in United Therapeutics by 5.1% in the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company's stock valued at $281,000 after acquiring an additional 23 shares in the last quarter. Bryn Mawr Trust Advisors LLC boosted its stake in United Therapeutics by 5.4% during the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company's stock valued at $276,000 after purchasing an additional 24 shares during the last quarter. Finally, Parallel Advisors LLC boosted its stake in United Therapeutics by 2.1% during the 3rd quarter. Parallel Advisors LLC now owns 1,154 shares of the biotechnology company's stock valued at $625,000 after purchasing an additional 24 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

United Therapeutics News Roundup

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Q3 revenue rose 4% year over year to $832.5 million, above Wall Street expectations of about $781 million. Q3 2026 financial results
• Positive Sentiment: United Therapeutics announced a buydown of the Pfizer royalty tied to ralinepag, a therapy for pulmonary arterial hypertension. Ending or reducing the royalty burden could improve the economics of the drug, though the reports provided no financial terms. Ralinepag royalty buydown
• Neutral Sentiment: The company’s $2 billion share-repurchase authorization, approved in October, may support per-share results over time, but it is not a new announcement in today’s news. United Therapeutics stock coverage
• Negative Sentiment: Q3 earnings were $5.71 per share, below analysts’ roughly $6.01 consensus and down from $7.16 a year earlier. The earnings miss and falling net income temper the strong revenue comparison. Q3 earnings miss
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares, about 2.84% of her direct holdings. The sale may add a modest negative signal, though it leaves her with a substantial stake. SEC insider transaction filing

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company's portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.